NASDAQ · SGMT
Healthcare · Biotechnology
$9.92
Down-$0.51 (-4.89%)
Updated Nov 1, 2026, 12:29 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SGMT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
SGMT closed at $9.92 after 21 trading sessions, up 8.53% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $10.41 | $10.535 | $9.82 | $9.92 | 989.15K |
| Oct 29, 2026 | $10.82 | $10.92 | $10.27 | $10.43 | 746.45K |
| Oct 28, 2026 | $10.32 | $10.76 | $10.2586 | $10.74 | 1.24M |
| Oct 27, 2026 | $9.58 | $10.48 | $9.55 | $10.42 | 1.11M |
| Oct 26, 2026 | $9.61 | $9.70 | $9.41 | $9.56 | 767.19K |
| Oct 23, 2026 | $9.95 | $9.95 | $9.495 | $9.58 | 694.95K |
| Oct 22, 2026 | $10.00 | $10.15 | $9.628 | $9.95 | 1.01M |
| Oct 21, 2026 | $9.76 | $10.21 | $9.72 | $9.99 | 1.58M |
| Oct 20, 2026 | $8.88 | $10.15 | $8.83 | $9.74 | 2.18M |
| Oct 19, 2026 | $8.24 | $9.005 | $8.15 | $8.86 | 1.69M |
| Oct 16, 2026 | $8.15 | $8.25 | $7.94 | $8.02 | 1.09M |
| Oct 15, 2026 | $7.61 | $8.275 | $7.54 | $8.17 | 1.37M |
| Oct 14, 2026 | $7.78 | $8.00 | $7.51 | $7.545 | 1.99M |
| Oct 13, 2026 | $8.70 | $8.74 | $7.88 | $7.98 | 2.52M |
| Oct 12, 2026 | $8.85 | $9.1453 | $8.735 | $8.80 | 1.16M |
| Oct 9, 2026 | $8.84 | $9.05 | $8.78 | $8.93 | 763.53K |
| Oct 8, 2026 | $8.80 | $8.94 | $8.63 | $8.92 | 1.23M |
| Oct 7, 2026 | $8.65 | $8.97 | $8.5984 | $8.88 | 631.65K |
| Oct 6, 2026 | $8.99 | $8.99 | $8.55 | $8.76 | 896.38K |
| Oct 5, 2026 | $9.075 | $9.12 | $8.40 | $9.03 | 1.53M |
| Oct 2, 2026 | $9.26 | $9.38 | $8.88 | $9.14 | 1.71M |
The latest Smart Investors Daily articles mentioning SGMT.
Company
Market Activity
Research & News
SGMT research
Company profile and research snapshot.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 2, 2026 | Guggenheim | Buy | — |
| Oct 1, 2026 | Oppenheimer | Outperform | — |
| Oct 1, 2026 | Citizens | Market Outperform | — |
| Sep 24, 2026 | Goldman Sachs | Sell | — |
No generated briefing is available yet.
Yahoo · Oct 23, 2026
The consensus price target hints at a 168.2% upside potential for Sagimet Biosciences Inc. (SGMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Yahoo · Oct 23, 2026
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announced that its strategic partner, Sagimet Biosciences Inc. ("Sagimet"), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key lipid synthesis regulator, for acne, had dosed the first patient in AURORA, Sagimet's pivotal U.S. Phase III clinical trial of denifanstat (ASC40) in adults and adolescents aged 12 years and older with moderate to severe acne. AURORA is intended to support a potential U.S. Ne
Yahoo · Oct 22, 2026
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal trial designed to enroll approximately 800 U.S. patients, including 450 adolescents aged 12 and olderIf approved, denifanstat has the potential to address a significant unmet need among approximately 10 million Americans with moderate to severe acne FOSTER CITY, Calif., Oct. 22, 2026 (GLO
Benzinga · Oct 22, 2026
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner AscletisPivotal
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SGMT.
